Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | PDC*lung01 + Pembrolizumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | lung non-small cell carcinoma | predicted - sensitive | PDC*lung01 + Pembrolizumab | Phase Ib/II | Actionable | In a Phase I/II trial, treatment with the combination of PDC*lung01 and Keytruda (pembrolizumab) demonstrated safety in non-small cell lung cancer patients with CD274 (PD-L1) expression (>=50%) and resulted in an objective response rate of 63.2% (12/19, all partial responses), a disease control rate of 94.7%, a median progression-free survival of 10.9 months, and a median duration of response of 9.49 months (Cancer Res (2024) 84 (7_Supplement): CT021; NCT03970746). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC | Full reference... |